/ People /
As managing partner of Medison Ventures, Gil applies his vast experience in business strategy, management consulting, corporate finance, private equity and capital markets, gained from his time as VP Corporate Development of Medison Group, Vice President of private equity fund Shamrock, and board member of several Israeli and international companies. Gil holds an MBA from the Recanati Business School at Tel Aviv University.
DR. YAEL GRUENBAUM-COHEN
Yael was appointed rare disease lead of Medison Ventures following four years as medical manager of Medison Group’s rare disease division, in which time she supported over 17 products and pre-launched seven, including Spinraza. A DMD and a Ph.D., before joining Medison Yael conducted post-doctoral research at the Weizmann Institute of Science. She also has a clinical background gained through eight years at the Hadassah Medical Center, where she was an attending in the department of oral and maxillofacial rehabilitation, and a lecturer in development and genetics.
DR. GOOZY HARTOG
As head of digital health & innovation at Medison Ventures, Goozy manages collaborations, forms partnerships and assesses investment opportunities.
His relevant previous experience includes working with Solution Lab to support young biotech companies through commercialization, and consulting on multiple pharma projects for multinational companies, with the Boston Consulting Group. Goozy holds a Ph.D. in neurobiology, from New York College.
DR. MATAN OFIR
Matan joined Medison Group in 2016. Prior to that, as business development associate at Cold Genesys in Los Angeles, he was responsible for evaluating tech opportunities and supporting development teams. Matan holds a Ph.D. in biology from Bar-Ilan University, and was part of a post-doctoral fellowship program at City of Hope National Medical Center in California, researching the function of non-coding RNA and the immune system.
DR. INBAL MICHAILOVICI
Before joining Medison to lead hematology, Inbal served as business development manager at BiolineRx, where her role included tech evaluation and management of the company portfolio. Prior to that, she was a senior lecturer in medical science at Ben-Gurion University of the Negev. Inbal holds a Ph.D. in signal transduction and embryonic muscle development, from the Weizmann Institute of Science.
DR. GIDEON PELCHOVITZ
Gideon came to Medison Ventures in 2016, from a role as biotech equity analyst at Nexthera Capital Hedge Fund. He holds a Ph.D. in microbiology from Tel-Aviv University and as a post-doc worked in the lab of Nobel Laureate, Prof. Ada Yonath, at the Weizmann Institute of Science.
DR. YAEL POMERANTZ
Yael is digital health lead at Medison Ventures. Her previous experience includes leading a team of healthcare and pharma consultants at Signals Analytics, a startup that provides business intelligence insights through big data analytics. Yael holds a Ph.D. in molecular biology of fertility from the Weizmann Institute of Science, and completed her post doctorate in stem cell research at the University of Texas, Austin.
DR. ASSAF TSUR
Assaf is the portfolio manager of Medison’s healthcare-focused hedge fund. Before joining Medison, he was a senior analyst at Nexthera Capital, New York, where he primarily covered the field of oncology. Assaf has also served as a biotech consultant at L1 Capital, New York, and as a biotech analyst at Natalitix, Israel. He holds a Ph.D. in developmental processes that govern tissue homeostasis in health and disease, from Tel Aviv University.
Tami joined the Medison Ventures in 2017. In her capacity as executive assistant to the team, Tami supports all aspects of coordination and logistics. Prior to joining Medison, Tami worked at Janssen Pharmaceutical (part of Johnson’s and Johnson companies) as a compliance assistant responsible for auditing all the company activities. Prior to that Tami was the marketing assistant of the Immunology Unit at Janssen. Tami holds a M.Sc in Biotechnology Managing from the Hebrew University and a B.A in Biology from Bar Ilan University.